A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Advances in molecular profiling and a greater understanding of the underlying biology are reinforcing the concept of a distinct disease from other ER-positive breast cancers
The 2026 ESMO Breast Cancer Awardee, Daniel F. Hayes, reflects on the future of biomarker research in the field
A pilot study reports high levels of acceptance and compliance despite an older patient population
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
A new ESMO consensus-driven document provides definitions, formats and minimum required data to uniform enumeration and reporting of prior lines of therapy across solid tumours
COMPASS trial suggests that selecting treatment based on subtypes classification may impact patients’ outcomes, but the approach is hard to implement in clinical practice
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.